RU2008120027A - Анти-addl моноклональное антитело и его применение - Google Patents

Анти-addl моноклональное антитело и его применение Download PDF

Info

Publication number
RU2008120027A
RU2008120027A RU2008120027/13A RU2008120027A RU2008120027A RU 2008120027 A RU2008120027 A RU 2008120027A RU 2008120027/13 A RU2008120027/13 A RU 2008120027/13A RU 2008120027 A RU2008120027 A RU 2008120027A RU 2008120027 A RU2008120027 A RU 2008120027A
Authority
RU
Russia
Prior art keywords
diffusing
ligands
derivatives
xaa
seq
Prior art date
Application number
RU2008120027/13A
Other languages
English (en)
Russian (ru)
Inventor
Джин КИННИ (US)
Джин КИННИ
Уилльям Р. СТРОЛ (US)
Уилльям Р. СТРОЛ
Чжицян АНЬ (US)
Чжицян АНЬ
Original Assignee
Мерк энд Ко., Инк. (US)
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк энд Ко., Инк. (US), Мерк Энд Ко., Инк. filed Critical Мерк энд Ко., Инк. (US)
Publication of RU2008120027A publication Critical patent/RU2008120027A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2008120027/13A 2005-10-21 2006-10-17 Анти-addl моноклональное антитело и его применение RU2008120027A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005381125 2005-10-21
USPCT/US2005/038125 2005-10-21

Publications (1)

Publication Number Publication Date
RU2008120027A true RU2008120027A (ru) 2009-11-27

Family

ID=39671607

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008120027/13A RU2008120027A (ru) 2005-10-21 2006-10-17 Анти-addl моноклональное антитело и его применение

Country Status (8)

Country Link
EP (1) EP1940466B1 (https=)
JP (1) JP5289963B2 (https=)
CN (1) CN101291692A (https=)
AU (1) AU2006306553B9 (https=)
CA (1) CA2626783A1 (https=)
NO (1) NO20082288L (https=)
RU (1) RU2008120027A (https=)
WO (1) WO2007050359A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
BR112012014060B8 (pt) 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
KR20140072019A (ko) * 2011-07-13 2014-06-12 머크 샤프 앤드 돔 코포레이션 체액 샘플에서의 아밀로이드 베타 올리고머의 검출 방법 및 그의 용도
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
EP1545582A4 (en) * 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof

Also Published As

Publication number Publication date
AU2006306553B2 (en) 2011-08-25
WO2007050359A2 (en) 2007-05-03
EP1940466B1 (en) 2012-11-28
EP1940466A2 (en) 2008-07-09
JP5289963B2 (ja) 2013-09-11
AU2006306553B9 (en) 2011-09-29
CA2626783A1 (en) 2007-05-03
CN101291692A (zh) 2008-10-22
EP1940466A4 (en) 2010-04-07
JP2009519895A (ja) 2009-05-21
AU2006306553A1 (en) 2007-05-03
WO2007050359A3 (en) 2007-06-21
WO2007050359A8 (en) 2008-05-08
NO20082288L (no) 2008-05-19

Similar Documents

Publication Publication Date Title
RU2008120027A (ru) Анти-addl моноклональное антитело и его применение
Fujii et al. D-Amino acids in protein: The mirror of life as a molecular index of aging
RU2013106270A (ru) Моноклональное антитело против addl и его применения
EP2749646B1 (en) IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME
US6319897B1 (en) Peptides which inhibit complement activation
Arnon et al. Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate
JP2009519895A5 (https=)
RU2014102007A (ru) Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов
JPWO2003085399A1 (ja) 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬
JP2013542914A5 (https=)
EP3186273A1 (en) Targeting immunotherapy for amyloidosis
RU2017103527A (ru) ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β(Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20070128191A1 (en) Polyclonal antibodies, preparation method thereof and use of same
ES2201929B1 (es) Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
EP0752425B1 (en) Peptide ligands for the constant region of immunoglobulins
Katsoyannis et al. [47] The synthesis of peptides by homogeneous solution procedures
AU2016344146A1 (en) Methods of measuring Factor D activity and potency of Factor D inhibitors
US7074765B2 (en) Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
US11104705B2 (en) Methods for removing bacterial toxins from a biological fluid
Galati et al. Increased resistance of peptides to serum proteases by modification of their amino groups
CA2518066A1 (en) Diagnosis of autism
JP2000221191A (ja) ヒト障害についての診断マ―カ―
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
US6222011B1 (en) Antigenic peptides
CA2488127A1 (en) Antibodies directed against prothrombin fragment f1+2, the preparation and use thereof

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20100312